Affymetrix - Part II - 500 Beiträge pro Seite
eröffnet am 28.06.00 18:02:28 von
neuester Beitrag 31.07.00 20:19:46 von
neuester Beitrag 31.07.00 20:19:46 von
Beiträge: 39
ID: 170.058
ID: 170.058
Aufrufe heute: 0
Gesamt: 1.514
Gesamt: 1.514
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 245 | |
| gestern 19:02 | 80 | |
| gestern 22:58 | 74 | |
| gestern 11:56 | 55 | |
| vor 1 Stunde | 43 | |
| vor 1 Stunde | 42 | |
| gestern 21:36 | 37 | |
| gestern 23:08 | 34 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.503,00 | +0,34 | 294 | |||
| 2. | 2. | 174,17 | -2,05 | 109 | |||
| 3. | 3. | 10,230 | +447,06 | 107 | |||
| 4. | 4. | 0,1935 | +2,38 | 77 | |||
| 5. | 7. | 0,9600 | -14,29 | 70 | |||
| 6. | 6. | 1,1100 | -3,48 | 60 | |||
| 7. | 5. | 4,1725 | -5,17 | 57 | |||
| 8. | 8. | 5,9840 | -1,55 | 48 |
Feedback
Da der alte THread ausgelaugt scheint, hier mal ein neuer
Wie ihr sehtbefindet sich AFFx zur Zeit in einer Trading Range zwischen rund 160$ und knapp über 200$.
Auffällig ist, dass die 160er MArke schon desöfteren guten Support gegeben hat!
Wie ihr sehtbefindet sich AFFx zur Zeit in einer Trading Range zwischen rund 160$ und knapp über 200$.
Auffällig ist, dass die 160er MArke schon desöfteren guten Support gegeben hat!
The patent infringement suit will probably cause some short-term volatility and potential long term damage. Has AFFX officially commented on this?
++++++++++++++++++++++++
July 5, 2000 8:46pm
Celera parent sues Affymetrix in dispute over 5 gene patents
Reuters
WILMINGTON, Del., July 5, (Reuters) - PE Corp., the parent of Celera Genomics Group , alleged in a lawsuit it filed Wednesday that Affymetrix Inc. products infringe five PE patents used to speed up DNA sequencing and to develop new human therapies.
In papers filed in the U.S. District Court in Delaware, PE alleged that Affymetrix "has long been aware of the patents" but continued to make and sell its GeneChip Probe Array which allegedly infringes the PE inventions. Affymetrix analyzes and manages genetic information and is 22 percent owned by Glaxo Wellcome Plc .
The lawsuit came as investors shifted their money from software maker stocks to U.S. biotech stocks. Analysts say the hope is for a continuing rebound in the biotech sector that was spurred by last week`s announcement that Celera and government researchers had completed the first big step toward mapping the human genetic code.
According to court papers, the patents at issue are used in the synthesis of oligonucleotides and can reduce, sometimes from days to minutes, the time needed to synthesize the genetic building block DNA, or deoxyribonucleic acid.
PE, also the parent of PE Biosystems Group , a provider of instruments, software and reagents to the life science industry, wants the court to block Affymetrix from further alleged infringement and to award unspecified but triple damages. An Affymetrix spokeswoman declined comment at this time.
++++++++++++++++++++++++
July 5, 2000 8:46pm
Celera parent sues Affymetrix in dispute over 5 gene patents
Reuters
WILMINGTON, Del., July 5, (Reuters) - PE Corp., the parent of Celera Genomics Group , alleged in a lawsuit it filed Wednesday that Affymetrix Inc. products infringe five PE patents used to speed up DNA sequencing and to develop new human therapies.
In papers filed in the U.S. District Court in Delaware, PE alleged that Affymetrix "has long been aware of the patents" but continued to make and sell its GeneChip Probe Array which allegedly infringes the PE inventions. Affymetrix analyzes and manages genetic information and is 22 percent owned by Glaxo Wellcome Plc .
The lawsuit came as investors shifted their money from software maker stocks to U.S. biotech stocks. Analysts say the hope is for a continuing rebound in the biotech sector that was spurred by last week`s announcement that Celera and government researchers had completed the first big step toward mapping the human genetic code.
According to court papers, the patents at issue are used in the synthesis of oligonucleotides and can reduce, sometimes from days to minutes, the time needed to synthesize the genetic building block DNA, or deoxyribonucleic acid.
PE, also the parent of PE Biosystems Group , a provider of instruments, software and reagents to the life science industry, wants the court to block Affymetrix from further alleged infringement and to award unspecified but triple damages. An Affymetrix spokeswoman declined comment at this time.
iwa, gut, dass wir mal wieder mit frischer energie an meinen biotech-favoriten rangehen.
offensichtlich konnte affymetrix nach der vollendung der bodenformation keinen richtigen aufwind erlangen.
woran lag das?
ist da was dran, was poor one sagt?
oder ist das nur eine konsolidierung vor dem nächsten boom?
antwort?
epicuraul
offensichtlich konnte affymetrix nach der vollendung der bodenformation keinen richtigen aufwind erlangen.
woran lag das?
ist da was dran, was poor one sagt?
oder ist das nur eine konsolidierung vor dem nächsten boom?
antwort?
epicuraul
Tja, so wie`s aussieht, ist an den Patentverstößen wohl doch was dran...
Affymetrix hat heute kurz vor Handelsbeginn mehr als knapp Stellung bezogen (siehe http://biz.yahoo.com/prnews/000706/ca_affymet.html).
Es heißt lapidar, man beziehe die betreffenden Reagenzen von PE-lizensierten Händlern und sehe gute Chancen, sich gegen die Klage
zu verteidigen. Wenn ich mich nicht irre, ist das schon die zweite Klage, die gegen AFFX anhängig ist?
Die Reaktionen des Marktes ließen jedenfalls nicht lange auf sich warten; die wichtige Unterstützung von 160$ ist zumindest zur Zeit
unterschritten, auch wenn zwischenzeitlich schon wieder Kurse von 164$ bezahlt wurden. Und plötzlich wundert es mich auch gar nicht
mehr, daß AFFX die letzten zwei Wochen nicht besonders lief... Wer das wohl schon alles vorher gewußt hat?
Gruß, ml
P.S.: Weiß jemand, worum es bei diesen Patentverstößen genau geht und was AFFX schlimmstenfalls droht?
Affymetrix hat heute kurz vor Handelsbeginn mehr als knapp Stellung bezogen (siehe http://biz.yahoo.com/prnews/000706/ca_affymet.html).
Es heißt lapidar, man beziehe die betreffenden Reagenzen von PE-lizensierten Händlern und sehe gute Chancen, sich gegen die Klage
zu verteidigen. Wenn ich mich nicht irre, ist das schon die zweite Klage, die gegen AFFX anhängig ist?
Die Reaktionen des Marktes ließen jedenfalls nicht lange auf sich warten; die wichtige Unterstützung von 160$ ist zumindest zur Zeit
unterschritten, auch wenn zwischenzeitlich schon wieder Kurse von 164$ bezahlt wurden. Und plötzlich wundert es mich auch gar nicht
mehr, daß AFFX die letzten zwei Wochen nicht besonders lief... Wer das wohl schon alles vorher gewußt hat?
Gruß, ml
P.S.: Weiß jemand, worum es bei diesen Patentverstößen genau geht und was AFFX schlimmstenfalls droht?
Trading Spotlight
Man kann das Verbot bekommen, mit dieser Technik in den USA weiterzuarbeiten, was ein ganzes Geschäftsmodell plötzlich zum Einstürzen bringen kann.
Meist einigt man sich aber auf (extrem saftige) Stafzahlungen + Lizenzgebühren. Jedenfalls lässt es den Gewinn schmelzen ... und den Kurs sinken.
Meist einigt man sich aber auf (extrem saftige) Stafzahlungen + Lizenzgebühren. Jedenfalls lässt es den Gewinn schmelzen ... und den Kurs sinken.
also das könnte den AFFX kurz doch schon belasten. Überlege zur Zeit, mich im Biochip und Screening Bereich neu zu postionieren
PE Corp. Claims Ownership Of Life`s Building Blocks
By Matthew Herper
Who has the right to make a gene? That is the question at the center of a lawsuit between biotechnology giant PE Corporation and Affymetrix, a company that revolutionized genetic analysis.
In a patent infringement lawsuit against Affymetrix (Nasdaq: AFFX - news), PE says it not only owns the five chemicals used to synthesize genetic code but has a patent on the process in which they are used. PE is suing Affymetrix for using these five chemicals in this patented process.
Affymetrix of Santa Clara, Calif., has used these substances since the company`s 1993 inception, and they are essential to Affymetrix`s gene chip technology, a powerful genetic analysis tool that speeds scientific research. These same chemicals were vital in the sequencing of the human genome, a task accomplished by PE subsidiary, Celera Genomics (NYSE: CRA - news).
Affymetrix says it bought the chemicals it used from the Norwalk, Conn.-based PE
and other companies licensed by PE. But PE is claiming that these purchases did not give Affymetrix the right to use the chemicals to make DNA. ``We believe we have certain exclusive rights to these chemicals,`` says Jay Rhodes, PE`s manager of media relations.
These chemicals are the base pairs that make up the genetic code. They are the chemicals used to synthesize the DNA on Affymetrix`s gene chips, but they`re not just used to make DNA. They are DNA; at least, they`re the part of the DNA in which the genetic code is written.
The DNA molecule looks like a ladder that has been twisted into a double spiral. All genetic information, including the body`s basic design, is encoded in patterns on the rungs of this ladder. There are four possible rungs that can be on this ladder, and the code is written in combinations of these rungs.
Four of the chemicals in question are the rungs of this ladder, and these are the base pairs. The fifth is a chemical that the body uses to decode the information on the rungs and turn it into the proteins that make up most of the body. So these chemicals are essential for making Affymetrix`s gene chips, which are silicon chips in which the base pairs are made to stick up like the hooks on a piece of Velcro. But they are also important in all sorts of genetic technologies.
The chemicals used to make the base pairs were developed nearly 20 years ago at the University of Colorado by professor Marvin Caruthers. He compares owning the patents to this technology to owning the only patents for the automobile; nobody else can make a car without your permission. He doesn`t care much about the patents himself because ``The University sold them.``
PE is probably just trying to squeeze some extra money out of these patents, some of which will run out next year. In the meantime, however, keeping tight control of these chemicals could wreak havoc in the biotech industry if PE targets other companies as it is targeting Affymetrix.
In doing so, however, PE would only be hurting its own Celera, which is a flashy company that can only be successful in a thriving biotech sector. Celera is, after all, selling a service: tools for analyzing DNA. This is worthless if other companies are unwilling or unable to buy it.
By Matthew Herper
Who has the right to make a gene? That is the question at the center of a lawsuit between biotechnology giant PE Corporation and Affymetrix, a company that revolutionized genetic analysis.
In a patent infringement lawsuit against Affymetrix (Nasdaq: AFFX - news), PE says it not only owns the five chemicals used to synthesize genetic code but has a patent on the process in which they are used. PE is suing Affymetrix for using these five chemicals in this patented process.
Affymetrix of Santa Clara, Calif., has used these substances since the company`s 1993 inception, and they are essential to Affymetrix`s gene chip technology, a powerful genetic analysis tool that speeds scientific research. These same chemicals were vital in the sequencing of the human genome, a task accomplished by PE subsidiary, Celera Genomics (NYSE: CRA - news).
Affymetrix says it bought the chemicals it used from the Norwalk, Conn.-based PE
and other companies licensed by PE. But PE is claiming that these purchases did not give Affymetrix the right to use the chemicals to make DNA. ``We believe we have certain exclusive rights to these chemicals,`` says Jay Rhodes, PE`s manager of media relations.
These chemicals are the base pairs that make up the genetic code. They are the chemicals used to synthesize the DNA on Affymetrix`s gene chips, but they`re not just used to make DNA. They are DNA; at least, they`re the part of the DNA in which the genetic code is written.
The DNA molecule looks like a ladder that has been twisted into a double spiral. All genetic information, including the body`s basic design, is encoded in patterns on the rungs of this ladder. There are four possible rungs that can be on this ladder, and the code is written in combinations of these rungs.
Four of the chemicals in question are the rungs of this ladder, and these are the base pairs. The fifth is a chemical that the body uses to decode the information on the rungs and turn it into the proteins that make up most of the body. So these chemicals are essential for making Affymetrix`s gene chips, which are silicon chips in which the base pairs are made to stick up like the hooks on a piece of Velcro. But they are also important in all sorts of genetic technologies.
The chemicals used to make the base pairs were developed nearly 20 years ago at the University of Colorado by professor Marvin Caruthers. He compares owning the patents to this technology to owning the only patents for the automobile; nobody else can make a car without your permission. He doesn`t care much about the patents himself because ``The University sold them.``
PE is probably just trying to squeeze some extra money out of these patents, some of which will run out next year. In the meantime, however, keeping tight control of these chemicals could wreak havoc in the biotech industry if PE targets other companies as it is targeting Affymetrix.
In doing so, however, PE would only be hurting its own Celera, which is a flashy company that can only be successful in a thriving biotech sector. Celera is, after all, selling a service: tools for analyzing DNA. This is worthless if other companies are unwilling or unable to buy it.
Hallo Montana, was häst du als großer AFFx Fan von der ganzen Sache.
Anscheinend hat mir das Schoicksal mal wieder eine Streich gespielt, denn AFFX kaufte ich aufgrund einer Entdeckung in meinen Keller.
Dort wurden mit Bleistift verschiedene Striche vor rund 15 Jahren ohne erkennbareIntention angebracht..
Diese ergänzen sich zu AFFX, dem Börsenkürzel von Affxmetrix.
Na ja, war natürlich nicht der Hauptgrund, aber die Geschichte ist wirklich wahr. Wenn ihc irgendwan aml eine Digi-Kamera habe, poste ich das Bild hier mal
Anscheinend hat mir das Schoicksal mal wieder eine Streich gespielt, denn AFFX kaufte ich aufgrund einer Entdeckung in meinen Keller.
Dort wurden mit Bleistift verschiedene Striche vor rund 15 Jahren ohne erkennbareIntention angebracht..
Diese ergänzen sich zu AFFX, dem Börsenkürzel von Affxmetrix.
Na ja, war natürlich nicht der Hauptgrund, aber die Geschichte ist wirklich wahr. Wenn ihc irgendwan aml eine Digi-Kamera habe, poste ich das Bild hier mal
also auf gehts Montana, hoffe morgen bzw. heute deine Meinung zu hören!
Affymetrix schließt Vertrag mit Janssen
Affymetrix (Nasdaq: AFFX; WKN 901198) gab heute bekannt einen Easy Access™ Silver Vertrag mit der Janssen Research Foundation (JRF) und The R.W. Johnson Pharmaceutical Research Institute (PRI) geschlossen zu haben.
Die beiden Unternehmen gehören zum Johnson & Johnson Konzern (NYSE: JNJ). Der Easy Access™ Silver Vertrag ermöglicht dem JRF und PRI einen breiten Zugang zu Affymetrix standard und maßangefertigten GeneChip® Arrays, sowie den zugehörigen Instrumenten und Software zur Analyse von Genexpressionen.
Zusätzlich haben das JRF und PRI eine Lizenz für bestimmte Affymetrix Patente zur Produktion und Nutzung von Nukleinsäure Arrays für Genexpressions Experimente erworben.
„Wir sind erfreut über den großen Fortschritten des JRF und PRI durch die Nutzung von DNA Arrays in der pharmazeutischen Forschung und Entwicklung, und ihrer Entscheidung GeneChip Produkte zu ihren Forschungsbemühungen hinzuzunehmen,“ sagte Susan E. Siegel, Präsident von Affymetrix.
Affymetrix (Nasdaq: AFFX; WKN 901198) gab heute bekannt einen Easy Access™ Silver Vertrag mit der Janssen Research Foundation (JRF) und The R.W. Johnson Pharmaceutical Research Institute (PRI) geschlossen zu haben.
Die beiden Unternehmen gehören zum Johnson & Johnson Konzern (NYSE: JNJ). Der Easy Access™ Silver Vertrag ermöglicht dem JRF und PRI einen breiten Zugang zu Affymetrix standard und maßangefertigten GeneChip® Arrays, sowie den zugehörigen Instrumenten und Software zur Analyse von Genexpressionen.
Zusätzlich haben das JRF und PRI eine Lizenz für bestimmte Affymetrix Patente zur Produktion und Nutzung von Nukleinsäure Arrays für Genexpressions Experimente erworben.
„Wir sind erfreut über den großen Fortschritten des JRF und PRI durch die Nutzung von DNA Arrays in der pharmazeutischen Forschung und Entwicklung, und ihrer Entscheidung GeneChip Produkte zu ihren Forschungsbemühungen hinzuzunehmen,“ sagte Susan E. Siegel, Präsident von Affymetrix.
Steht demnächst bei Affymetrix ein Split an??
Wer weiss was davon??
Wer weiss was davon??
servus iwa,
habe nicht immer die zeit, die ich mir wünsche, um hier zu posten (das studium, der alkohol, die frau(en) usw. -
das geht tierisch an die substanz...).
ich denke die meldung ist in dem sinne zu verstehen, daß nichts so heiß gegessen wird wie es gekocht wird.
insbesondere nicht, wenn es um irgendwelche gerichtlichen verfahren geht.
ich muß dir allerdings gestehen, daß ich "meinem größten kunden" einen teilverkauf affx empfohlen habe - so bei
195/196$ - um in zwei andere werte einzusteigen. dies liegt allerdings auch daran, daß affx in dem besagten depot
stark übergewichtet war und es dies zu korrigieren galt.
der eine wert ist myriad. den anderen sende ich dir - nach absprache mit m.lynched - per email zu (habe ich nicht entdeckt,
und deshalb stelle ich den hier auch nicht rein). sehr interssant
finde ich im übrigen auch genzyme transgenetics - kennst du diesen wert genauer? gibt bei yahoo einen recht
interessanten bericht zu denen, wonach gztc auf dem weg sei, abgenix und medarex nachzueifern (was den erfolg
angeht). glaube mal sowas von proteintherapie gehört zu haben. hordenbach meinte mal vor einer gewissen zeit,
daß man sich unter medizinern einig sei, daß dieser bereich vor einer ganz großen zukunft steht.
bis dann,
Montana
ps: reg dich nicht mehr auf, das bringt einfach nichts - akzeptier das. je früher desto besser für dich - ich machs auch
nicht mehr. freue dich einfach über die leute hier, die ok sind. die ganzen rest verarschen wir einfach ;-)
habe nicht immer die zeit, die ich mir wünsche, um hier zu posten (das studium, der alkohol, die frau(en) usw. -
das geht tierisch an die substanz...).
ich denke die meldung ist in dem sinne zu verstehen, daß nichts so heiß gegessen wird wie es gekocht wird.
insbesondere nicht, wenn es um irgendwelche gerichtlichen verfahren geht.
ich muß dir allerdings gestehen, daß ich "meinem größten kunden" einen teilverkauf affx empfohlen habe - so bei
195/196$ - um in zwei andere werte einzusteigen. dies liegt allerdings auch daran, daß affx in dem besagten depot
stark übergewichtet war und es dies zu korrigieren galt.
der eine wert ist myriad. den anderen sende ich dir - nach absprache mit m.lynched - per email zu (habe ich nicht entdeckt,
und deshalb stelle ich den hier auch nicht rein). sehr interssant
finde ich im übrigen auch genzyme transgenetics - kennst du diesen wert genauer? gibt bei yahoo einen recht
interessanten bericht zu denen, wonach gztc auf dem weg sei, abgenix und medarex nachzueifern (was den erfolg
angeht). glaube mal sowas von proteintherapie gehört zu haben. hordenbach meinte mal vor einer gewissen zeit,
daß man sich unter medizinern einig sei, daß dieser bereich vor einer ganz großen zukunft steht.
bis dann,
Montana
ps: reg dich nicht mehr auf, das bringt einfach nichts - akzeptier das. je früher desto besser für dich - ich machs auch
nicht mehr. freue dich einfach über die leute hier, die ok sind. die ganzen rest verarschen wir einfach ;-)
zur Zeit wird häufig an AFFX herumgenörgelt, da sie eine hohe Bewertung hätten,
aber 1. gutes ist nie billig und AFFX ist Weltmarktführer
2. wie MH schon sagte wird man für die Produktion von Biochips kaum um eine Lizenz von AFFX herumkommren, s. MWG Biotech
aber 1. gutes ist nie billig und AFFX ist Weltmarktführer
2. wie MH schon sagte wird man für die Produktion von Biochips kaum um eine Lizenz von AFFX herumkommren, s. MWG Biotech
dennoch scheint die Zeit der großen Kurssprünge erst mla vorbei zu sein
frauen? Plural meine ich, hast du etwa noch eine Schwester.?
Genzyme Transgenics GZTC
Schaut euch die meldungen und den chart bei yahoo an.
Vor 2 Monaten habe ich mir ausnahmsweise über zacks einen research über die kommen lassen. Woran die arbeiten und welches potential darin steckt, ist unglaublich.
GZTC bringt artfremde gene in erbanalgen von tieren wie z.B. mäuse, schafe, rinder etc., damit sie hilfreiche stoffe wie z.B. insulin produzieren. Besonders milchkühe sind prädistiniert. Die produzieren dann milch mit den gewünschten inhaltsstoffen. Das braucht dann nur noch filtriert werden. Denkt mal daran, wieviel milch eine hochleistungkuh pro jahr schaffen kann !
Heute werden hauptsächlich bakterien eingesetzt, die die gewünschten stoffe produzieren, aber das bringt eine menge schwierigkeiten mit sich (zucht der bakterien, gewinnung der stoffe etc.).
Medikamente von tieren "produzieren" lassen ist ein gigantischer Zukunftsmarkt !!!
Bis bald.
PS: Der report ist von Greenwich Global L.P., erschienen am 30. april 1999. Ein kurzer folgereport erschien am 4. august 1999. Auch zu aurora habe ich zwei reports kommen lassen. Auch beide sehr informtiv und positiv. Allerdings scheint mir die konkurrenz auf deren sektor weitaus höher.
Schaut euch die meldungen und den chart bei yahoo an.
Vor 2 Monaten habe ich mir ausnahmsweise über zacks einen research über die kommen lassen. Woran die arbeiten und welches potential darin steckt, ist unglaublich.
GZTC bringt artfremde gene in erbanalgen von tieren wie z.B. mäuse, schafe, rinder etc., damit sie hilfreiche stoffe wie z.B. insulin produzieren. Besonders milchkühe sind prädistiniert. Die produzieren dann milch mit den gewünschten inhaltsstoffen. Das braucht dann nur noch filtriert werden. Denkt mal daran, wieviel milch eine hochleistungkuh pro jahr schaffen kann !
Heute werden hauptsächlich bakterien eingesetzt, die die gewünschten stoffe produzieren, aber das bringt eine menge schwierigkeiten mit sich (zucht der bakterien, gewinnung der stoffe etc.).
Medikamente von tieren "produzieren" lassen ist ein gigantischer Zukunftsmarkt !!!
Bis bald.
PS: Der report ist von Greenwich Global L.P., erschienen am 30. april 1999. Ein kurzer folgereport erschien am 4. august 1999. Auch zu aurora habe ich zwei reports kommen lassen. Auch beide sehr informtiv und positiv. Allerdings scheint mir die konkurrenz auf deren sektor weitaus höher.
aber dazu solten wir einen eignene Thread aufmachen, ansonsten sollten wir uns hier auf AFFX konzentrieren
Für einen evt. Reduzierung von AFFX in meinem Depot werde icherst mla die nächsten Tage abwarten
und wieder der CHart, damit er oben ist, wenn ich nur die letzten 20 Postings öffne 
Deltagen to Use Affymetrix GeneChip(R) Arrays to Build Murine
7/14/00 4:16:00 AM
Source: PR Newswire
Gene Expression Databases
SANTA CLARA, Calif., July 14 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX) announced today that Deltagen, Inc. will use Affymetrix` GeneChip(R) probe arrays to build and commercialize DeltaXpress(TM) databases of gene expression information utilizing Deltagen`s proprietary knockout mouse models. Deltagen plans to market its DeltaXpress gene expression databases to pharmaceutical and biotechnology companies to assist them in efficiently leveraging genomics advances into new medicines.
Quote Snapshot
AFFX 188.31 6.31
· Messages
Enter symbol:
· Symbol Lookup
sponsored by
Quotes delayed 20+ minutes
Trade Now
with our broker sponsors
Deltagen utilizes proprietary molecular biology systems to disrupt or "knock out" genes in mice on a large scale and conducts detailed mammalian gene function analyses on the resulting physiological, pathological and behavioral effects in these proprietary knockout animals. Deltagen intends to utilize Affymetrix` GeneChip probe arrays to analyze gene expression levels in these knockout mice to complement its existing DeltaBase(TM) mammalian gene function discovery database program. The databases will be valuable alone or in combination with Affymetrix` GeneChip probe arrays or any GATC-compatible products to accelerate drug target discovery and validation.
Under the agreement, Deltagen will pay Affymetrix annual subscription fees for access to GeneChip technology, purchase probe arrays, related instrumentation and software, and pay royalties to Affymetrix on database subscription fees.
"Today`s agreement with Deltagen emphasizes our strategy of providing researchers with a broad array of standardized and complementary tools to understand complex genetic information," said Susan E. Siegel, President of Affymetrix. "We are pleased to collaborate with Deltagen in its efforts to decipher genome function. Affymetrix` GeneChip technology enables Deltagen to combine gene expression information with its knockout mouse model system. We believe this powerful combination will accelerate the drug discovery successes of the genomics community."
Deltagen`s databases will be designed to be compatible with standards outlined by the GATC. GATC compliance would enable users to use GATC-compliant bioinformatics software and to compare data from the Deltagen databases with data from their own or others` experiments conducted using GeneChip probe arrays or other systems that provide GATC-compliant data.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
7/14/00 4:16:00 AM
Source: PR Newswire
Gene Expression Databases
SANTA CLARA, Calif., July 14 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX) announced today that Deltagen, Inc. will use Affymetrix` GeneChip(R) probe arrays to build and commercialize DeltaXpress(TM) databases of gene expression information utilizing Deltagen`s proprietary knockout mouse models. Deltagen plans to market its DeltaXpress gene expression databases to pharmaceutical and biotechnology companies to assist them in efficiently leveraging genomics advances into new medicines.
Quote Snapshot
AFFX 188.31 6.31
· Messages
Enter symbol:
· Symbol Lookup
sponsored by
Quotes delayed 20+ minutes
Trade Now
with our broker sponsors
Deltagen utilizes proprietary molecular biology systems to disrupt or "knock out" genes in mice on a large scale and conducts detailed mammalian gene function analyses on the resulting physiological, pathological and behavioral effects in these proprietary knockout animals. Deltagen intends to utilize Affymetrix` GeneChip probe arrays to analyze gene expression levels in these knockout mice to complement its existing DeltaBase(TM) mammalian gene function discovery database program. The databases will be valuable alone or in combination with Affymetrix` GeneChip probe arrays or any GATC-compatible products to accelerate drug target discovery and validation.
Under the agreement, Deltagen will pay Affymetrix annual subscription fees for access to GeneChip technology, purchase probe arrays, related instrumentation and software, and pay royalties to Affymetrix on database subscription fees.
"Today`s agreement with Deltagen emphasizes our strategy of providing researchers with a broad array of standardized and complementary tools to understand complex genetic information," said Susan E. Siegel, President of Affymetrix. "We are pleased to collaborate with Deltagen in its efforts to decipher genome function. Affymetrix` GeneChip technology enables Deltagen to combine gene expression information with its knockout mouse model system. We believe this powerful combination will accelerate the drug discovery successes of the genomics community."
Deltagen`s databases will be designed to be compatible with standards outlined by the GATC. GATC compliance would enable users to use GATC-compliant bioinformatics software and to compare data from the Deltagen databases with data from their own or others` experiments conducted using GeneChip probe arrays or other systems that provide GATC-compliant data.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
Affymetrix Signs GeneChip(R) EasyAccess(TM) Silver Agreement
7/10/00 4:16:00 AM
Source: PR Newswire
With Janssen Research Foundation and The R.W. Johnson Pharmaceutical Research Institute Janssen Research Foundation and The R.W. Johnson Pharmaceutical Research Institute Obtain Access to Affymetrix GeneChip Arrays and a License From Affymetrix for Worldwide Internal Nucleic Acid Array Spotting Initiatives
Quote Snapshot
JNJ 91.81 -3.44
AFFX 188.31 6.31
· Messages
Enter symbol:
· Symbol Lookup
sponsored by
Quotes delayed 20+ minutes
Trade Now
with our broker sponsors
SANTA CLARA, Calif., July 10 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX) announced today that it has entered into agreements with Janssen Research Foundation (JRF) and The R.W. Johnson Pharmaceutical Research Institute (PRI), both members of the Johnson & Johnson family of companies (NYSE: JNJ). JRF and PRI have entered into an EasyAccess(TM) Silver agreement under which JRF and PRI will gain broad access to Affymetrix` standard and custom GeneChip(R) arrays, instrumentation and software to monitor gene expression for use in their pharmaceutical research and development activities.
JRF and PRI have also taken a license to certain Affymetrix patents to produce and use nucleic acid arrays for gene expression monitoring experiments conducted as part of JRF`s and PRI`s internal research efforts.
"We are delighted with the tremendous progress made by JRF and PRI using DNA arrays for pharmaceutical research and development, and in their decision to add GeneChip products to their research discovery efforts," said Susan E. Siegel, President of Affymetrix.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip(R) system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Annual Report on Form 10-K for the year ended December 31, 1999. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
7/10/00 4:16:00 AM
Source: PR Newswire
With Janssen Research Foundation and The R.W. Johnson Pharmaceutical Research Institute Janssen Research Foundation and The R.W. Johnson Pharmaceutical Research Institute Obtain Access to Affymetrix GeneChip Arrays and a License From Affymetrix for Worldwide Internal Nucleic Acid Array Spotting Initiatives
Quote Snapshot
JNJ 91.81 -3.44
AFFX 188.31 6.31
· Messages
Enter symbol:
· Symbol Lookup
sponsored by
Quotes delayed 20+ minutes
Trade Now
with our broker sponsors
SANTA CLARA, Calif., July 10 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX) announced today that it has entered into agreements with Janssen Research Foundation (JRF) and The R.W. Johnson Pharmaceutical Research Institute (PRI), both members of the Johnson & Johnson family of companies (NYSE: JNJ). JRF and PRI have entered into an EasyAccess(TM) Silver agreement under which JRF and PRI will gain broad access to Affymetrix` standard and custom GeneChip(R) arrays, instrumentation and software to monitor gene expression for use in their pharmaceutical research and development activities.
JRF and PRI have also taken a license to certain Affymetrix patents to produce and use nucleic acid arrays for gene expression monitoring experiments conducted as part of JRF`s and PRI`s internal research efforts.
"We are delighted with the tremendous progress made by JRF and PRI using DNA arrays for pharmaceutical research and development, and in their decision to add GeneChip products to their research discovery efforts," said Susan E. Siegel, President of Affymetrix.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip(R) system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Annual Report on Form 10-K for the year ended December 31, 1999. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE Affymetrix, Inc.
bin fast froh über die negativ Meldung wg. CRA, da jetzt endlich mal wieder jemand über AFFX redet
sehr toll, AFFX scheint heute zum dritten MAl am Wiederstand von 200$ zu scheitern
Bei nicht Break ist wohl wieder ein Kurs von 155-160 $ intraday zu erwarten. Der Aufwärtstrend, den F. in seinem Heft so schön herausheben wollte verläuft bei 165$
Danke nochmal für die Daten zu AFFX.
Scheint sich so langsam wieder anzuziehen. Die Fa hat eine Marktkapitalisierung von rund 5 Mrd $, also
noch viel Luft nach oben.
Was mich allerdings etwas verwirrt und mich von weiteren Investments in die Aktie etwas abhält ist der
Rechtsstreit mit Celera. Das kann doch außerordentlich teuer werden. Der Venter ist doch alles andere als ein
lieber zuvorkommender Mensch. Der wird dich alles versuchen, um von Affymetrix Royakties zu sehen
Was meint Ihr?
Kann das nicht bei entsprechenden Meldungen über Gerichtstermine etc zu herben Kursrückschlägen führen?
Stehe momentan vor dem Problem, einige Aktien umzuschichten und eigentlich sollte AFFY aufgestockt werden.
Kommen da demnächst Kursrückschläge?
Danke
CCC
Scheint sich so langsam wieder anzuziehen. Die Fa hat eine Marktkapitalisierung von rund 5 Mrd $, also
noch viel Luft nach oben.
Was mich allerdings etwas verwirrt und mich von weiteren Investments in die Aktie etwas abhält ist der
Rechtsstreit mit Celera. Das kann doch außerordentlich teuer werden. Der Venter ist doch alles andere als ein
lieber zuvorkommender Mensch. Der wird dich alles versuchen, um von Affymetrix Royakties zu sehen
Was meint Ihr?
Kann das nicht bei entsprechenden Meldungen über Gerichtstermine etc zu herben Kursrückschlägen führen?
Stehe momentan vor dem Problem, einige Aktien umzuschichten und eigentlich sollte AFFY aufgestockt werden.
Kommen da demnächst Kursrückschläge?
Danke
CCC
Affymetrix splits 2 for 1
--10:19 am - By Tomi Kilgore
Affymetrix (AFFX: news, msgs) is rising 7 7/16 to 197 3/4. The analyzer and manager of genetic information said that its board of directors have approved the 2-for-1 split of its stock. The split will be payable Aug. 21 for shareholders of record after the close of business on Aug. 10. This will increase the number of shares outstanding to 55.2 million. The stock has nearly doubled in the past three months.
--10:19 am - By Tomi Kilgore
Affymetrix (AFFX: news, msgs) is rising 7 7/16 to 197 3/4. The analyzer and manager of genetic information said that its board of directors have approved the 2-for-1 split of its stock. The split will be payable Aug. 21 for shareholders of record after the close of business on Aug. 10. This will increase the number of shares outstanding to 55.2 million. The stock has nearly doubled in the past three months.
Affymetrix Announces Two-for-One Stock Split
SANTA CLARA, Calif., July 21 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX - news) announced today that its Board of Directors has approved a two-for-one stock split of the Company`s outstanding shares of common stock.
The stock split entitles each stockholder of record at the close of business on August 10, 2000, to receive a stock dividend of one additional share for every share of Affymetrix Common Stock held on that date. The additional shares resulting from the stock split will be distributed by the Company`s transfer agent on August 21, 2000.
The Company currently has approximately 27.6 million shares outstanding. Upon completion of the split, the number will increase to approximately 55.2 million.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip® system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` ``expectations,`` ``beliefs,`` ``hopes,`` ``intentions,`` ``strategies`` or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE: Affymetrix, Inc.
SANTA CLARA, Calif., July 21 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX - news) announced today that its Board of Directors has approved a two-for-one stock split of the Company`s outstanding shares of common stock.
The stock split entitles each stockholder of record at the close of business on August 10, 2000, to receive a stock dividend of one additional share for every share of Affymetrix Common Stock held on that date. The additional shares resulting from the stock split will be distributed by the Company`s transfer agent on August 21, 2000.
The Company currently has approximately 27.6 million shares outstanding. Upon completion of the split, the number will increase to approximately 55.2 million.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip® system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` ``expectations,`` ``beliefs,`` ``hopes,`` ``intentions,`` ``strategies`` or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
SOURCE: Affymetrix, Inc.
Affymetrix Reports Record Second Quarter Results
Company Introduces Whole Genome Scanning Project
SANTA CLARA, Calif., July 24 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX - news) today reported results for the second quarter of 2000. For the quarter ended June 30, 2000, total revenue increased 82% to $45.4 million, up from revenue of $24.9 million for the quarter ended June 30, 1999. For the first six months of 2000, revenue increased 92% to $85.6 million, up from revenue of $44.6 million for the first six months of 1999. Product sales increased 79% to $40.2 million for the quarter ended June 30, 2000 compared to $22.5 million in the comparable period of 1999. For the six months ended June 30, 2000, product revenues were $76.9 million, an increase of 94% over the comparable period in 1999. The increase in product sales during the quarter and six months of 2000 over the comparable periods in 1999 was the result of increased sales of GeneChip® probe arrays, increased placements of instruments (primarily the GeneChip system and components, the 417 Arrayer(TM) and the 418 Scanner(TM)) and increased subscription fees earned under EasyAccess(TM) contracts. Other revenues, which include licensing fees, royalties and research revenue, were $5.2 million for the quarter ended June 30, 2000 and $8.8 million for the six months ended June 30, 2000, compared to $2.4 million and $5.0 million in the corresponding periods of 1999. The increase in other revenues was attributable primarily to the signing of additional licenses and the expansion of existing licensing arrangements.
Total costs and expenses increased to $53.2 million for the quarter ended June 30, 2000, from $33.7 million for the comparable period in 1999. For the first six months of 2000, total costs and expenses increased to $101.1 million, compared to $61.6 million for the same period in 1999. The increase in operating expenses resulted primarily from the Company`s expansion of commercial activities including those of GMS and increased legal costs arising from ongoing patent litigation.
The Company reported a net loss attributable to Common Stockholders of $6.1 million, or $0.22 per diluted share for the quarter ended June 30, 2000, compared to a net loss attributable to Common Stockholders of $8.3 million, or $0.33 per diluted share, for the comparable period in 1999.
During the second quarter, demand for Affymetrix` products continued to grow as researchers seeking to understand genetic variation and its role in health and disease continued to embrace DNA array technology.
Affymetrix achieved record instrument placements leading to an installed base at the end of the quarter of more than 300 GeneChip systems and more than 450 Affymetrix spotted Arrayers and Scanners. Chip shipments and subscription revenues also achieved record levels in the quarter driven by the growing use of the Company`s technology and acceptance of its EasyAccess program. Notable in the quarter were EasyAccess Silver agreements with the Janssen Research Foundation (JRF) and The R.W. Johnson Pharmaceutical Research Institute (PRI), both members of the Johnson & Johnson family of companies, Merck and Co., Inc., and Procter & Gamble Company. Affymetrix also signed numerous AcademicAccess(TM) supply agreements, bringing the total number of participating institutions to over 60 at the end of the quarter.
In addition to new supply agreements, Affymetrix also entered into collaborations to commercialize powerful databases using GeneChip technology. In April Affymetrix signed an agreement with InphoGene BioCom, Inc., to develop an internet-based expression database relating to cardiopulmonary disease. In July Deltagen, Inc. entered into an agreement with the Company to use GeneChip arrays to build databases of gene expression information utilizing Deltagen`s proprietary knockout mouse models. These databases will be valuable alone or in combination with Affymetrix` GeneChip probe arrays or any GATC-compatible products to accelerate drug target discovery and validation.
Affymetrix also continued its commitment to enabling the DNA array field through its licensing program. Notable in the quarter were internal use license agreements entered into with Merck, JRF and PRI as well as a commercial use license granted to MWG-Biotech AG to allow them to make and sell low and medium density pre-spotted DNA arrays (up to 5,000 spots/slide).
In addition the Company continued to advance its core manufacturing technology to deliver the promise of Moore`s Law to the field of DNA arrays. Affymetrix followed Moore`s Law for the second time in three years this quarter with the launch of new human and murine array sets. Through feature size reductions and other improvements, these third generation 20 micron feature arrays generate nearly eight times as much information as their 50 micron predecessor products did only three years ago. In the same time frame, the cost per data point to the customer has fallen at more than twice this rate.
Progress made over the past several months from our core technology research efforts suggest that Affymetrix will be able to continue to achieve the benefits of Moore`s Law both near and long term. To exploit these advances, Affymetrix has embarked on an internal research initiative known as the Genome Scanning Project to realize the possibility of cost-effectively analyzing the entire human genome. The goals of the project are to achieve orders of magnitude improvements in the efficiency of scanning the human genome and to lay the foundation for the day when whole genome scanning will be commonplace. The ability to cost-effectively scan the entire genome will not only revolutionize the medical research field, but will also usher in a new scientific era. Affymetrix is now on a firm technical foundation to make this happen.
Investors may listen to Affymetrix` management discuss this announcement by dialing domestic: 800-205-6714; international: 415-908-4758; passcode - 1959 on Monday, July 24, from 2:00-3:00 p.m. PDT. A replay of this call will be available for 24 hours, domestic: 800-633-8284; international: 858-812-6440; passcode - 15739028.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip® system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost-efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` ``expectations,`` ``beliefs,`` ``hopes,`` ``intentions,`` ``strategies`` or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
AFFYMETRIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In thousands)
June 30, December 31,
2000 1999
(Unaudited) (Note)
ASSETS
Current assets:
Cash and cash equivalents $85,247 $12,677
Available-for-sale securities 334,325 213,763
Accounts receivable 38,028 24,646
Inventories 17,011 12,792
Other current assets 1,785 4,159
Total current assets 476,396 268,037
Net property and equipment 49,006 40,775
Acquired technology rights 10,433 8,965
Notes receivable from stockholders 1,022 1,074
Other assets 52,129 7,736
$588,986 $326,587
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable and accrued liabilities $36,360 $29,926
Deferred revenue 9,700 6,468
Current portion of capital lease obligation 135 261
Total current liabilities 46,195 36,655
Obligation to Beckman Coulter, Inc. 5,000 5,000
Convertible subordinated notes 375,000 150,000
Common stock purchase rights 3,000 3,000
Stockholders` equity:
Common stock 276 271
Additional paid-in-capital 263,213 256,739
Accumulated deficit (136,564) (124,203)
Other 32,866 (875)
Total stockholders` equity 159,791 131,932
$588,986 $326,587
Note: The balance sheet at December 31, 1999 has been derived from the
supplemental audited consolidated financial statements at that date
included in the Company`s Form 8-K filed on April 7, 2000, but does
not include all of the information and footnotes required by
generally accepted accounting principles for complete financial
statements.
Affymetrix, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2000 1999 2000 1999
Revenue:
Product $40,182 $22,482 $76,855 $39,576
Research 440 1,872 2,874 4,316
License fees and royalties 4,789 539 5,913 736
Total revenue 45,411 24,893 85,642 44,628
Costs and expenses:
Cost of product revenue 17,211 10,801 30,717 17,140
Research and development 12,952 10,120 25,160 20,651
Selling, general and
administrative 23,050 12,782 42,801 23,844
Merger acquisition costs -- -- 2,395 --
Total costs and expenses 53,213 33,703 101,073 61,635
Loss from operations (7,802) (8,810) (15,431) (17,007)
Interest income, net 1,710 1,308 3,070 2,391
Net loss (6,092) (7,502) (12,361) (14,616)
Preferred Stock dividends -- (813) -- (1,626)
Net loss attributable to
Common Stockholders $(6,092) $(8,315) $(12,361) $(16,242)
Basic and diluted net loss
per common share $(0.22) $(0.33) $(0.46) $(0.66)
Shares used to calculate
basic and diluted net loss
per common share 27,495 25,162 27,163 24,706
Note: Certain prior year balances have been reclassified to conform with
the current year presentations.
SOURCE: Affymetrix, Inc.
Email this story - View most popular stories emailed
Company Introduces Whole Genome Scanning Project
SANTA CLARA, Calif., July 24 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX - news) today reported results for the second quarter of 2000. For the quarter ended June 30, 2000, total revenue increased 82% to $45.4 million, up from revenue of $24.9 million for the quarter ended June 30, 1999. For the first six months of 2000, revenue increased 92% to $85.6 million, up from revenue of $44.6 million for the first six months of 1999. Product sales increased 79% to $40.2 million for the quarter ended June 30, 2000 compared to $22.5 million in the comparable period of 1999. For the six months ended June 30, 2000, product revenues were $76.9 million, an increase of 94% over the comparable period in 1999. The increase in product sales during the quarter and six months of 2000 over the comparable periods in 1999 was the result of increased sales of GeneChip® probe arrays, increased placements of instruments (primarily the GeneChip system and components, the 417 Arrayer(TM) and the 418 Scanner(TM)) and increased subscription fees earned under EasyAccess(TM) contracts. Other revenues, which include licensing fees, royalties and research revenue, were $5.2 million for the quarter ended June 30, 2000 and $8.8 million for the six months ended June 30, 2000, compared to $2.4 million and $5.0 million in the corresponding periods of 1999. The increase in other revenues was attributable primarily to the signing of additional licenses and the expansion of existing licensing arrangements.
Total costs and expenses increased to $53.2 million for the quarter ended June 30, 2000, from $33.7 million for the comparable period in 1999. For the first six months of 2000, total costs and expenses increased to $101.1 million, compared to $61.6 million for the same period in 1999. The increase in operating expenses resulted primarily from the Company`s expansion of commercial activities including those of GMS and increased legal costs arising from ongoing patent litigation.
The Company reported a net loss attributable to Common Stockholders of $6.1 million, or $0.22 per diluted share for the quarter ended June 30, 2000, compared to a net loss attributable to Common Stockholders of $8.3 million, or $0.33 per diluted share, for the comparable period in 1999.
During the second quarter, demand for Affymetrix` products continued to grow as researchers seeking to understand genetic variation and its role in health and disease continued to embrace DNA array technology.
Affymetrix achieved record instrument placements leading to an installed base at the end of the quarter of more than 300 GeneChip systems and more than 450 Affymetrix spotted Arrayers and Scanners. Chip shipments and subscription revenues also achieved record levels in the quarter driven by the growing use of the Company`s technology and acceptance of its EasyAccess program. Notable in the quarter were EasyAccess Silver agreements with the Janssen Research Foundation (JRF) and The R.W. Johnson Pharmaceutical Research Institute (PRI), both members of the Johnson & Johnson family of companies, Merck and Co., Inc., and Procter & Gamble Company. Affymetrix also signed numerous AcademicAccess(TM) supply agreements, bringing the total number of participating institutions to over 60 at the end of the quarter.
In addition to new supply agreements, Affymetrix also entered into collaborations to commercialize powerful databases using GeneChip technology. In April Affymetrix signed an agreement with InphoGene BioCom, Inc., to develop an internet-based expression database relating to cardiopulmonary disease. In July Deltagen, Inc. entered into an agreement with the Company to use GeneChip arrays to build databases of gene expression information utilizing Deltagen`s proprietary knockout mouse models. These databases will be valuable alone or in combination with Affymetrix` GeneChip probe arrays or any GATC-compatible products to accelerate drug target discovery and validation.
Affymetrix also continued its commitment to enabling the DNA array field through its licensing program. Notable in the quarter were internal use license agreements entered into with Merck, JRF and PRI as well as a commercial use license granted to MWG-Biotech AG to allow them to make and sell low and medium density pre-spotted DNA arrays (up to 5,000 spots/slide).
In addition the Company continued to advance its core manufacturing technology to deliver the promise of Moore`s Law to the field of DNA arrays. Affymetrix followed Moore`s Law for the second time in three years this quarter with the launch of new human and murine array sets. Through feature size reductions and other improvements, these third generation 20 micron feature arrays generate nearly eight times as much information as their 50 micron predecessor products did only three years ago. In the same time frame, the cost per data point to the customer has fallen at more than twice this rate.
Progress made over the past several months from our core technology research efforts suggest that Affymetrix will be able to continue to achieve the benefits of Moore`s Law both near and long term. To exploit these advances, Affymetrix has embarked on an internal research initiative known as the Genome Scanning Project to realize the possibility of cost-effectively analyzing the entire human genome. The goals of the project are to achieve orders of magnitude improvements in the efficiency of scanning the human genome and to lay the foundation for the day when whole genome scanning will be commonplace. The ability to cost-effectively scan the entire genome will not only revolutionize the medical research field, but will also usher in a new scientific era. Affymetrix is now on a firm technical foundation to make this happen.
Investors may listen to Affymetrix` management discuss this announcement by dialing domestic: 800-205-6714; international: 415-908-4758; passcode - 1959 on Monday, July 24, from 2:00-3:00 p.m. PDT. A replay of this call will be available for 24 hours, domestic: 800-633-8284; international: 858-812-6440; passcode - 15739028.
Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip® system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost-efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` ``expectations,`` ``beliefs,`` ``hopes,`` ``intentions,`` ``strategies`` or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.
AFFYMETRIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In thousands)
June 30, December 31,
2000 1999
(Unaudited) (Note)
ASSETS
Current assets:
Cash and cash equivalents $85,247 $12,677
Available-for-sale securities 334,325 213,763
Accounts receivable 38,028 24,646
Inventories 17,011 12,792
Other current assets 1,785 4,159
Total current assets 476,396 268,037
Net property and equipment 49,006 40,775
Acquired technology rights 10,433 8,965
Notes receivable from stockholders 1,022 1,074
Other assets 52,129 7,736
$588,986 $326,587
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable and accrued liabilities $36,360 $29,926
Deferred revenue 9,700 6,468
Current portion of capital lease obligation 135 261
Total current liabilities 46,195 36,655
Obligation to Beckman Coulter, Inc. 5,000 5,000
Convertible subordinated notes 375,000 150,000
Common stock purchase rights 3,000 3,000
Stockholders` equity:
Common stock 276 271
Additional paid-in-capital 263,213 256,739
Accumulated deficit (136,564) (124,203)
Other 32,866 (875)
Total stockholders` equity 159,791 131,932
$588,986 $326,587
Note: The balance sheet at December 31, 1999 has been derived from the
supplemental audited consolidated financial statements at that date
included in the Company`s Form 8-K filed on April 7, 2000, but does
not include all of the information and footnotes required by
generally accepted accounting principles for complete financial
statements.
Affymetrix, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2000 1999 2000 1999
Revenue:
Product $40,182 $22,482 $76,855 $39,576
Research 440 1,872 2,874 4,316
License fees and royalties 4,789 539 5,913 736
Total revenue 45,411 24,893 85,642 44,628
Costs and expenses:
Cost of product revenue 17,211 10,801 30,717 17,140
Research and development 12,952 10,120 25,160 20,651
Selling, general and
administrative 23,050 12,782 42,801 23,844
Merger acquisition costs -- -- 2,395 --
Total costs and expenses 53,213 33,703 101,073 61,635
Loss from operations (7,802) (8,810) (15,431) (17,007)
Interest income, net 1,710 1,308 3,070 2,391
Net loss (6,092) (7,502) (12,361) (14,616)
Preferred Stock dividends -- (813) -- (1,626)
Net loss attributable to
Common Stockholders $(6,092) $(8,315) $(12,361) $(16,242)
Basic and diluted net loss
per common share $(0.22) $(0.33) $(0.46) $(0.66)
Shares used to calculate
basic and diluted net loss
per common share 27,495 25,162 27,163 24,706
Note: Certain prior year balances have been reclassified to conform with
the current year presentations.
SOURCE: Affymetrix, Inc.
Email this story - View most popular stories emailed
Affymetrix posts bigger than-expected quarterly loss
SANTA CLARA, Calif., July 24 (Reuters) - Affymetrix Inc. (NasdaqNM:AFFX - news), a supplier of technology used to analyse genetic information, on Monday reported a second-quarter operating loss that was bigger than what Wall Street had expected.
The Santa Clara, Calif.-based company said its loss from operations narrowed to $6.1 million, or 22 cents a share, from a net loss of $8.3 million, or 33 cents for the comparable 1999 period.
Analysts, however, had on average expected Affymetrix to lose 15 cents a share, according to First Call/Thomson Financial, which tracks earnings estimates.
Revenues for the quarter climbed to $45.4 million from $24.9 million from a year earlier. Affymetrix attributed most of its revenue growth to product sales, particularly increased sales of its GeneChip system, which is used to analyse and manage complex genetic information.
Affymetrix licenses its systems to drug companies and academic researchers working on ways to use the genetic code to discover the causes of disease and find ways to make drugs work better.
Email this story - View most popular stories emailed
SANTA CLARA, Calif., July 24 (Reuters) - Affymetrix Inc. (NasdaqNM:AFFX - news), a supplier of technology used to analyse genetic information, on Monday reported a second-quarter operating loss that was bigger than what Wall Street had expected.
The Santa Clara, Calif.-based company said its loss from operations narrowed to $6.1 million, or 22 cents a share, from a net loss of $8.3 million, or 33 cents for the comparable 1999 period.
Analysts, however, had on average expected Affymetrix to lose 15 cents a share, according to First Call/Thomson Financial, which tracks earnings estimates.
Revenues for the quarter climbed to $45.4 million from $24.9 million from a year earlier. Affymetrix attributed most of its revenue growth to product sales, particularly increased sales of its GeneChip system, which is used to analyse and manage complex genetic information.
Affymetrix licenses its systems to drug companies and academic researchers working on ways to use the genetic code to discover the causes of disease and find ways to make drugs work better.
Email this story - View most popular stories emailed
Unterstützungen: kurzfristiger Aufwärtstrend 171 $
GD100 und GD50 168
horizontal bei 155$ intraday
GD100 und GD50 168
horizontal bei 155$ intraday
nachbörslich bereits 177 5/16
ich würde jetzt auf keinen fall verkaufen - das hätte man wenn schon gestern nachbörslich tun müssen. jetzt
ist es eh zu spät. wahrscheinlich wird affx heute verprügelt werde, obwohl ich mir nicht ganz sicher bin. die
nachbörslichen kurse basieren auf sehr dünnen umsätzen (einige wenige tausend, die mit abstand größte order
war eine 8500er).
die erfahrung lehrt, dass anleger nach unerwarteten ergebnissen häufig vöiig unbesonnen reagieren und zahlen
völlig falsch interpretiert werden. sollte affx extrem verprügelt werdem, sind das klare nachkaufchancen.
kurzfristig sieht es jedoch faktisch nicht gut aus für affx. für mich bleibt affx jedoch eines der basis-investments.
ciao,
Montana
ps: hi iwa, leider hatte ich keine möglichkeit, dir zu antworten. die nächsten tage wieder mehr!
ist es eh zu spät. wahrscheinlich wird affx heute verprügelt werde, obwohl ich mir nicht ganz sicher bin. die
nachbörslichen kurse basieren auf sehr dünnen umsätzen (einige wenige tausend, die mit abstand größte order
war eine 8500er).
die erfahrung lehrt, dass anleger nach unerwarteten ergebnissen häufig vöiig unbesonnen reagieren und zahlen
völlig falsch interpretiert werden. sollte affx extrem verprügelt werdem, sind das klare nachkaufchancen.
kurzfristig sieht es jedoch faktisch nicht gut aus für affx. für mich bleibt affx jedoch eines der basis-investments.
ciao,
Montana
ps: hi iwa, leider hatte ich keine möglichkeit, dir zu antworten. die nächsten tage wieder mehr!
Buckweiser goes Biotech...hab mir heute nachmittag zu 165 Euro AFFX gekauft, hoffe es war kein Fehler
Grüsse, buck
Grüsse, buck
Aha, also bislng keine drug delivering Companies,:
ansonsten heute lauter Bestätigungen seitens der Analysten:
Date Broker Report Source
7/25/00 Grunta Affymetrix Inc. Reiterated Short-Term `Market Perform` at Grunta Bloomberg
7/25/00 Robertson Stephens Affymetrix Inc. Reiterated `Strong Buy` at Robertson Stephens Bloomberg
7/25/00 Chase H&Q Affymetrix Inc. Reiterated `Market Perform` at Chase H&Q
tja AFFx heute 157,375 $ per schluss
insb. der Schlusskurschart verdeutlicht : net so toll zur Zeit, der Bereich um knapp über 160$, der häufig zum Auffingen diente ist gebreakt- würde eher mal abwarten
Neuengagements drängen sich noch nicht auf, die News von gestern müssen , obwohl AFFX denoch weiter auf Kurs bleibt, erstmal verdaut werden
kurzfristig eher 150$, nachdem jetzt die Zone um 160$ unterschritten wurde; eine Zone, die lange und oftmals hilet.
:ansonsten heute lauter Bestätigungen seitens der Analysten:
Date Broker Report Source
7/25/00 Grunta Affymetrix Inc. Reiterated Short-Term `Market Perform` at Grunta Bloomberg
7/25/00 Robertson Stephens Affymetrix Inc. Reiterated `Strong Buy` at Robertson Stephens Bloomberg
7/25/00 Chase H&Q Affymetrix Inc. Reiterated `Market Perform` at Chase H&Q
tja AFFx heute 157,375 $ per schluss
insb. der Schlusskurschart verdeutlicht : net so toll zur Zeit, der Bereich um knapp über 160$, der häufig zum Auffingen diente ist gebreakt- würde eher mal abwarten
Neuengagements drängen sich noch nicht auf, die News von gestern müssen , obwohl AFFX denoch weiter auf Kurs bleibt, erstmal verdaut werden
kurzfristig eher 150$, nachdem jetzt die Zone um 160$ unterschritten wurde; eine Zone, die lange und oftmals hilet.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 295 | ||
| 109 | ||
| 107 | ||
| 77 | ||
| 66 | ||
| 60 | ||
| 58 | ||
| 48 | ||
| 45 | ||
| 43 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 25 | ||
| 24 | ||
| 21 | ||
| 20 | ||
| 18 | ||
| 18 |
